Secondary analysis of the phase 3b BE RADIANT trial (743 patients with plaque psoriasis): bimekizumab vs secukinumab gave more patients with no itch, skin pain or scaling at 1 year (eg scaling 70.5% vs 49.7%; nominal P<.001), maintained to 3 years; switchers improved.
Secondary analysisn = 743
Augustin et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension